Dark

Check out our API

FSII
FS Development Corp. II Class A Common Stock
stock NASDAQ

Inactive

Dec 23, 2021

9.80USD-2.000%(-0.20)289,188

Pre-market

0.00USD-100.000%(-10.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 27, 2021

07:00AM EST Ongoing Phase I trial shows potential for stand-alone, unboosted agent against COVID-19 GlobeNewswire Inc

Dec 21, 2021

07:10AM EST FS Development Corp. And Pardes Biosciences Move Towards Merger RTTNews

07:00AM EST FSII and Pardes Biosciences Move Towards Merger With the Goal of Tackling COVID-19 via an Oral Antiviral for Treatment and Prevention of SARS-CoV-2 Infections Business Wire

Dec 1, 2021

11:38AM EST FS Development Corp. II Announces Effectiveness of Registration Statement for Proposed Business Combination with Pardes Special Meeting Scheduled for December 23, 2021 Business Wire

Sep 21, 2021

04:12PM EDT FS Development Corp II Merger Partner Pardes Bioscience Announces Issuance Of US Patent Benzinga

Aug 26, 2021

08:06AM EDT FS Development Corp. II Merger Partner Pardes Biosciences Initiates First-In-Human Trial For PBI-0451, An Oral Antiviral In Development To Treat And Prevent SARS-CoV-2 Infections Benzinga

08:00AM EDT Pardes Biosciences, Inc., a clinical-stage biopharmaceutical company today announced the initiation of a Phase 1 clinical trial, evaluating the companys lead candidate, PBI-0451 which is being developed as a potential oral direct-acting antiviral to treat and prevent infections with SARS-CoV-2, the virus that causes COVID-19. GlobeNewswire Inc

Aug 5, 2021

07:00AM EDT Pardes Biosciences, Inc., an early-stage biopharmaceutical company developing PBI-0451 as a potential direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, today announced the appointments of Deborah M. Autor and Laura J. Hamill to its Board of Directors. GlobeNewswire Inc

Jun 29, 2021

03:07PM EDT Gilead, Foresite Take Pardes Biosciences Public In $250M SPAC Deal Benzinga

06:07AM EDT Pardes Biosciences, FS Development Corp. II To Merge; Combined Co. To Be Named Pardes Biosciences, Ticker Symbol PRDS RTTNews

06:06AM EDT Pardes Biosciences To Go Public Through Merger With FS Development Corp. II; Total Proceeds From Transaction Expected To Be $276M Benzinga

06:00AM EDT Pardes Biosciences and FS Development Corp. II Announce Merger Agreement Creating Publicly Listed Biopharmaceutical Company Advancing Oral Antiviral Drugs to Treat and Prevent SARS-CoV-2 Infections Business Wire

Feb 17, 2021

11:36AM EST FS Development Corp. II Shares Open For Trade At $10.50; IPO Priced At $10/Unit Benzinga

09:40AM EST FS Development Corp. II Shares Will Open For Quote At 11:00 a.m. EST, Expected To Open For Trade After 11:10 a.m. EST; IPO Priced At $10/Unit Benzinga

Share